PINC gene delivery systems - Valentis
Latest Information Update: 21 May 2007
At a glance
- Originator Valentis
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 24 Apr 2007 This technology is available for sale or licensing (http://www.valentis.com)
- 13 Apr 2000 New profile
- 13 Apr 2000 Phase-II clinical trials for Undefined in USA (Injection)